Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8001 + BAT1306 in HER2-positive advanced solid tumors
ChiCTR1900022300Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Dec 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of BAT8001 and bat1306 in HER2-positive cancer (HER2+) (3 arms), sponsored by Shanghai East Hospital. Primary endpoints: Maximum tolerated dose and Recommended phase II dose. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
BAT8001bat1306
03
Conditions
HER2-positive cancer (HER2+)
Beyond the preview
Go deeper on ChiCTR1900022300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022300.